Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement
March 07, 2022 08:00 ET
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene...
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
January 20, 2022 07:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
January 13, 2022 08:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
December 17, 2021 08:00 ET
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
December 14, 2021 08:47 ET
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
December 02, 2021 08:00 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality
November 29, 2021 08:00 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition
November 19, 2021 06:00 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange...
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results
November 09, 2021 16:35 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
October 14, 2021 16:15 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...